“Realized through collaboration between ECOG-ACRIN, NCI, and Caris Life Sciences, this public-private partnership represents a methodological, logistical, and collaborative integration of datasets ...

ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences ® (Caris) announced today a multi-year research collaboration wherein Caris is pairing its highly sophisticated and comprehensive ...

In this secondary analysis of the ECOG-ACRIN E2906 study, researchers assessed vulnerabilities of AML patients aged 60 years or older and their affect on survival outcomes.

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human ...

Article ‘Count’ and ‘Share’ for ECOG-ACRIN Cancer Research Group based on listed parameters only. The articles listed below published by authors from ECOG-ACRIN Cancer Research Group, organized by ...

Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received chemotherapy before surgery to remove advanced squamous ...

New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current methods to predict recurrence risk in ...

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study This phase II trial of ...

The MarketWatch News Department was not involved in the creation of this content. New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger ...